Chimeric antigen receptor T-cell therapy - Juno Therapeutics

Drug Profile

Chimeric antigen receptor T-cell therapy - Juno Therapeutics

Alternative Names: Armored CAR modified T Cells; CD19-directed 4-1BBL armored CAR - Juno Therapeutics; EGFRt/19-28z/4-1BBL CAR T cells

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Juno Therapeutics
  • Developer Juno Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cell replacements; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia

Most Recent Events

  • 06 Mar 2018 Juno Therapeutics has been acquired by Celgene Corporation
  • 15 Mar 2017 Phase-I clinical trials in Chronic lymphocytic leukaemia (Refractory metastatic disease, Recurrent) in USA (Parenteral) (NCT03085173)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top